Drug Trial Radar · NCT05156320
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
188
Actual
Start
Apr 14, 2022
Primary completion
Dec 18, 2024
Study completion Dec 18, 2024
Sponsor
- Lead sponsor
- Scholar Rock, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 trial (Study SRK-015-003) was conducted in patients ≥2 years old at Screening, who were previously diagnosed with later-onset spinal muscular atrophy (SMA) (i.e., Type 2 and Type 3 SMA) and were receiving an approved survival motor neuron (SMN) upregulator therapy (i.e., either nusinersen or risdiplam), to confirm the efficacy and safety of apitegromab as an adjunctive therapy to nusinersen and evaluate the efficacy and safety of apitegromab as an adjunctive therapy to risdiplam.
Conditions
- Spinal Muscular Atrophy
- Spinal Muscular Atrophy Type 3
- Spinal Muscular Atrophy Type 2
- SMA
- Neuromuscular Diseases
- Muscular Atrophy
- Atrophy
- Muscular Atrophy, Spinal
- Neuromuscular Manifestations
- Anti-myostatin
Interventions
ApitegromabDrug
Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 was administered every 4 weeks by intravenous (IV) infusion.
PlaceboDrug
Placebo was administered every 4 weeks by intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main Efficacy Population: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) total score.Time frame: Baseline up to 12 months.
Locations
50 sites in 9 countries. Site status is shown where the registry gives one.
Children's of Alabama
Birmingham, Alabama
Phoenix Children's Hospital
Phoenix, Arizona
Children's Hospital of Los Angeles
Los Angeles, California
Stanford University Medical Center
Palo Alto, California
Rady's Children's Hospital/UCSD
San Diego, California
Children's Hospital Colorado
Aurora, Colorado
Nemours Children's Hospital
Orlando, Florida
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Iowa
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
The Johns Hopkins University
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
Helen DeVos Children's Hospital
Grand Rapids, Michigan
Gillette Children's Specialty Healthcare
Saint Paul, Minnesota
Washington University School of Medicine in St. Louis
St Louis, Missouri
Columbia University, SMA Clinical Research Center
New York, New York
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
Nationwide Children's Hospital
Columbus, Ohio
Oregon Health & Sciences University
Portland, Oregon
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania
St. Jude Children's Research Hospital
Memphis, Tennessee
Children's Medical Center Dallas
Dallas, Texas
University of Utah
Salt Lake City, Utah
Children's Hospital of The King's Daughters
Norfolk, Virginia
Seattle Children's Hospital
Seattle, Washington
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin
UZ Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Chr de La Citadelle
Liège, Belgium
CHU Lille - Hôpital Jeanne de Flandre
Lille, France
Hôpital Armand Trousseau, I-Motion
Paris, France
CHU Toulouse - Hopital des Enfants
Toulouse, France
Universitätsklinikum Bonn
Bonn, Germany
Universitätsklinikum Essen
Essen, Germany
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Germany
Dr. von Haunersches Kinderspital
Munich, Germany
IRCCS Istituto Giannina Gaslini
Genoa, Italy
A.O.U Policlinico G. Martino
Messina, Italy
Foundation I.R.C.C.S. Carlo Besta Neurological Institute
Milan, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.